XFOR Operating Income vs Reconciled Depreciation Analysis

XFOR Stock

USD 0.28 0.31 52.54%

X4 Pharmaceuticals financial indicator trend analysis is more than just analyzing X4 Pharmaceuticals current accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether X4 Pharmaceuticals is a good investment. Please check the relationship between X4 Pharmaceuticals Operating Income and its Reconciled Depreciation accounts. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in X4 Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

To learn how to invest in XFOR Stock, please use our How to Invest in X4 Pharmaceuticals guide.

Operating Income vs Reconciled Depreciation

Operating Income vs Reconciled Depreciation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of X4 Pharmaceuticals Operating Income account and Reconciled Depreciation. At this time, the significance of the direction appears to have pay attention.

The correlation between X4 Pharmaceuticals' Operating Income and Reconciled Depreciation is -0.82. Overlapping area represents the amount of variation of Operating Income that can explain the historical movement of Reconciled Depreciation in the same time period over historical financial statements of X4 Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of X4 Pharmaceuticals' Operating Income and Reconciled Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Operating Income of X4 Pharmaceuticals are associated (or correlated) with its Reconciled Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Reconciled Depreciation has no effect on the direction of Operating Income i.e., X4 Pharmaceuticals' Operating Income and Reconciled Depreciation go up and down completely randomly.

Correlation Coefficient

-0.82

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Operating Income

Operating Income is the amount of profit realized from X4 Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of X4 Pharmaceuticals is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Reconciled Depreciation

Most indicators from X4 Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into X4 Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in X4 Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons.

To learn how to invest in XFOR Stock, please use our How to Invest in X4 Pharmaceuticals guide.As of 11/14/2024, Enterprise Value is likely to grow to about 130.6 M, while Selling General Administrative is likely to drop slightly above 19.2 M.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	1.9M	2.0M	419K	398.1K
Interest Income	10K	219K	3.3M	3.5M

Depreciation And Amortization Interest Income

X4 Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Other Liab
Total Assets		0.85	0.79	0.75	0.94	0.77	0.35	-0.91	-0.78	0.75	0.99	0.9	0.61	0.99	-0.41	0.7	0.55	0.25	0.78	0.78	0.39	0.78	0.99	-0.62	0.63	0.55
Short Long Term Debt Total	0.85		0.93	0.91	0.67	0.87	0.14	-0.56	-0.89	0.85	0.78	0.85	0.49	0.81	-0.68	0.82	0.71	0.61	0.88	0.88	0.72	0.92	0.82	-0.46	0.74	0.67
Other Current Liab	0.79	0.93		0.94	0.57	0.81	-0.11	-0.51	-0.87	0.84	0.72	0.79	0.34	0.74	-0.58	0.81	0.7	0.71	0.82	0.86	0.8	0.85	0.75	-0.37	0.77	0.74
Total Current Liabilities	0.75	0.91	0.94		0.5	0.75	0.09	-0.49	-0.87	0.89	0.7	0.67	0.28	0.73	-0.67	0.84	0.72	0.78	0.83	0.84	0.87	0.79	0.74	-0.16	0.81	0.8
Total Stockholder Equity	0.94	0.67	0.57	0.5		0.63	0.46	-0.96	-0.62	0.56	0.96	0.82	0.65	0.95	-0.18	0.53	0.36	-0.09	0.64	0.63	0.07	0.63	0.94	-0.7	0.44	0.34
Property Plant And Equipment Net	0.77	0.87	0.81	0.75	0.63		0.03	-0.5	-0.74	0.69	0.69	0.88	0.61	0.69	-0.67	0.73	0.46	0.46	0.8	0.78	0.56	0.99	0.7	-0.45	0.52	0.45
Current Deferred Revenue	0.35	0.14	-0.11	0.09	0.46	0.03		-0.5	-0.23	0.25	0.43	0.04	0.22	0.43	-0.07	0.2	0.18	-0.32	0.32	0.23	-0.22	0.04	0.43	-0.17	0.22	0.17
Net Debt	-0.91	-0.56	-0.51	-0.49	-0.96	-0.5	-0.5		0.55	-0.53	-0.95	-0.71	-0.53	-0.94	0.1	-0.48	-0.32	0.08	-0.56	-0.55	-0.07	-0.5	-0.93	0.56	-0.44	-0.37
Retained Earnings	-0.78	-0.89	-0.87	-0.87	-0.62	-0.74	-0.23	0.55		-0.98	-0.74	-0.68	-0.21	-0.77	0.64	-0.96	-0.9	-0.53	-0.98	-0.99	-0.65	-0.78	-0.78	0.43	-0.94	-0.89
Accounts Payable	0.75	0.85	0.84	0.89	0.56	0.69	0.25	-0.53	-0.98		0.72	0.64	0.18	0.74	-0.71	0.95	0.92	0.61	0.96	0.96	0.71	0.73	0.75	-0.32	0.97	0.93
Cash	0.99	0.78	0.72	0.7	0.96	0.69	0.43	-0.95	-0.74	0.72		0.84	0.58	1.0	-0.33	0.67	0.5	0.16	0.75	0.74	0.32	0.7	1.0	-0.59	0.6	0.53
Non Current Assets Total	0.9	0.85	0.79	0.67	0.82	0.88	0.04	-0.71	-0.68	0.64	0.84		0.76	0.83	-0.51	0.6	0.45	0.31	0.7	0.71	0.43	0.88	0.83	-0.61	0.48	0.39
Non Currrent Assets Other	0.61	0.49	0.34	0.28	0.65	0.61	0.22	-0.53	-0.21	0.18	0.58	0.76		0.55	-0.21	0.09	-0.06	-0.06	0.29	0.26	0.03	0.58	0.55	-0.32	-0.04	-0.12
Cash And Short Term Investments	0.99	0.81	0.74	0.73	0.95	0.69	0.43	-0.94	-0.77	0.74	1.0	0.83	0.55		-0.36	0.69	0.55	0.21	0.77	0.76	0.36	0.71	1.0	-0.6	0.64	0.57
Net Receivables	-0.41	-0.68	-0.58	-0.67	-0.18	-0.67	-0.07	0.1	0.64	-0.71	-0.33	-0.51	-0.21	-0.36		-0.68	-0.66	-0.74	-0.68	-0.63	-0.76	-0.7	-0.37	0.09	-0.61	-0.58
Common Stock Total Equity	0.7	0.82	0.81	0.84	0.53	0.73	0.2	-0.48	-0.96	0.95	0.67	0.6	0.09	0.69	-0.68		0.85	0.54	0.96	0.95	0.65	0.76	0.7	-0.33	0.9	0.86
Common Stock Shares Outstanding	0.55	0.71	0.7	0.72	0.36	0.46	0.18	-0.32	-0.9	0.92	0.5	0.45	-0.06	0.55	-0.66	0.85		0.58	0.85	0.87	0.64	0.53	0.56	-0.35	0.97	0.93
Non Current Liabilities Total	0.25	0.61	0.71	0.78	-0.09	0.46	-0.32	0.08	-0.53	0.61	0.16	0.31	-0.06	0.21	-0.74	0.54	0.58		0.47	0.49	0.99	0.51	0.22	0.17	0.58	0.63
Other Current Assets	0.78	0.88	0.82	0.83	0.64	0.8	0.32	-0.56	-0.98	0.96	0.75	0.7	0.29	0.77	-0.68	0.96	0.85	0.47		0.99	0.59	0.83	0.78	-0.45	0.89	0.83
Other Stockholder Equity	0.78	0.88	0.86	0.84	0.63	0.78	0.23	-0.55	-0.99	0.96	0.74	0.71	0.26	0.76	-0.63	0.95	0.87	0.49	0.99		0.6	0.82	0.77	-0.47	0.92	0.86
Total Liab	0.39	0.72	0.8	0.87	0.07	0.56	-0.22	-0.07	-0.65	0.71	0.32	0.43	0.03	0.36	-0.76	0.65	0.64	0.99	0.59	0.6		0.61	0.37	0.09	0.67	0.71
Property Plant And Equipment Gross	0.78	0.92	0.85	0.79	0.63	0.99	0.04	-0.5	-0.78	0.73	0.7	0.88	0.58	0.71	-0.7	0.76	0.53	0.51	0.83	0.82	0.61		0.72	-0.47	0.57	0.51
Total Current Assets	0.99	0.82	0.75	0.74	0.94	0.7	0.43	-0.93	-0.78	0.75	1.0	0.83	0.55	1.0	-0.37	0.7	0.56	0.22	0.78	0.77	0.37	0.72		-0.59	0.65	0.58
Short Term Debt	-0.62	-0.46	-0.37	-0.16	-0.7	-0.45	-0.17	0.56	0.43	-0.32	-0.59	-0.61	-0.32	-0.6	0.09	-0.33	-0.35	0.17	-0.45	-0.47	0.09	-0.47	-0.59		-0.32	-0.23
Common Stock	0.63	0.74	0.77	0.81	0.44	0.52	0.22	-0.44	-0.94	0.97	0.6	0.48	-0.04	0.64	-0.61	0.9	0.97	0.58	0.89	0.92	0.67	0.57	0.65	-0.32		0.99
Other Liab	0.55	0.67	0.74	0.8	0.34	0.45	0.17	-0.37	-0.89	0.93	0.53	0.39	-0.12	0.57	-0.58	0.86	0.93	0.63	0.83	0.86	0.71	0.51	0.58	-0.23	0.99

Click cells to compare fundamentals

X4 Pharmaceuticals Account Relationship Matchups

X4 Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	160.7M	122.9M	117.2M	155.6M	147.3M	102.4M
Short Long Term Debt Total	22.9M	38.4M	39.8M	38.4M	58.3M	29.6M
Other Current Liab	6.5M	8.0M	7.9M	12.0M	12.8M	7.4M
Total Current Liabilities	9.4M	11.9M	14.0M	22.3M	22.9M	13.7M
Total Stockholder Equity	129.2M	72.8M	64.4M	74.1M	51.1M	46.6M
Property Plant And Equipment Net	2.4M	9.2M	10.2M	8.3M	6.4M	4.7M
Net Debt	(103.3M)	(40.3M)	(42.0M)	(83.3M)	(41.2M)	(43.2M)
Retained Earnings	(132.0M)	(194.2M)	(282.9M)	(376.7M)	(477.9M)	(454.0M)
Accounts Payable	2.1M	3.1M	4.3M	7.8M	8.9M	9.4M
Cash	126.2M	78.7M	81.8M	121.7M	99.5M	76.4M
Non Current Assets Total	31.4M	39.6M	29.3M	26.9M	25.2M	19.2M
Non Currrent Assets Other	1.9M	3.3M	1.7M	1.2M	654K	621.3K
Cash And Short Term Investments	126.2M	78.7M	81.8M	121.7M	114.5M	78.2M
Net Receivables	2.0M	917K	747K	1.2M	562K	533.9K
Common Stock Shares Outstanding	11.5M	20.1M	25.7M	63.5M	177.8M	186.7M
Liabilities And Stockholders Equity	160.7M	122.9M	117.2M	155.6M	147.3M	102.4M
Non Current Liabilities Total	22.0M	38.1M	38.7M	59.2M	73.3M	42.1M
Other Current Assets	1.1M	3.7M	5.3M	5.8M	7.0M	7.4M
Other Stockholder Equity	100.7M	267.1M	347.4M	450.8M	529.0M	555.4M
Total Liab	31.5M	50.1M	52.8M	81.5M	96.2M	55.9M
Property Plant And Equipment Gross	2.4M	9.2M	10.2M	8.3M	8.0M	4.9M
Total Current Assets	129.3M	83.3M	87.9M	128.7M	122.1M	83.3M
Short Term Debt	898K	786K	1.9M	2.5M	1.1M	1.7M
Other Liab	16K	462K	826K	23.3M	26.8M	28.1M
Net Tangible Assets	102.1M	45.7M	47.1M	56.7M	65.2M	68.5M
Long Term Debt	20.1M	33.2M	33.1M	32.3M	54.6M	27.7M
Short Long Term Debt	2.3M	1.7M	795K	1.3M	1.2M	1.8M
Non Current Liabilities Other	16K	462K	826K	3.6M	432K	748K
Property Plant Equipment	2.4M	9.2M	10.2M	1.1M	1.3M	1.2M
Capital Surpluse	156.6M	261.4M	267.1M	450.8M	518.4M	283.1M
Net Invested Capital	149.3M	106.0M	98.3M	107.7M	105.7M	104.9M
Net Working Capital	119.8M	71.4M	73.9M	106.4M	99.2M	89.4M

Pair Trading with X4 Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if X4 Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in X4 Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with XFOR Stock

0.7	ME	23Andme Holding	Pair Corr
0.63	VALN	Valneva SE ADR	Pair Corr

Moving against XFOR Stock

0.67	DRUG	Bright Minds Biosciences	Pair Corr
0.51	DMAC	DiaMedica Therapeutics	Pair Corr
0.51	SABSW	SAB Biotherapeutics	Pair Corr
0.43	VCYT	Veracyte	Pair Corr
0.33	VIGL	Vigil Neuroscience	Pair Corr

The ability to find closely correlated positions to X4 Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace X4 Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back X4 Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling X4 Pharmaceuticals to buy it.

The correlation of X4 Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as X4 Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if X4 Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for X4 Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for XFOR Stock Analysis

When running X4 Pharmaceuticals' price analysis, check to measure X4 Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy X4 Pharmaceuticals is operating at the current time. Most of X4 Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of X4 Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move X4 Pharmaceuticals' price. Additionally, you may evaluate how the addition of X4 Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC